Dr. Gregory M.T. Hare and Dr. C. David Mazer
Back row left to right: Charmagne Crescini, Sanjay Yagnik, Mikhil Mistry, Esther Lee
Hare-Mazer laboratory research has focused on defining adaptive, and maladaptive, cardiovascular mechanisms in integrative translational models of anemia, bleeding and transfusion. They have established whole animal physiological models for assessing oxygen delivery to tissue utilizing tissue Doppler measurement of blood flow and light based in vivo measurements of tissue PO2. These outcomes are compared with molecular readouts of hypoxic gene expression during acute anemia and transfusion. By coupling these physiological outcome measurements with molecular signals of tissue hypoxia, including RNA, protein and immunohistochemical analysis, they have defined hypoxic mechanisms (HIF, nNOS) of anemia-induced mortality. Utilizing these methods we continue to assess the degree cardiovascular adaptation to acute anemia and transfusion in the whole animal, and clinical models in order to gain further insight into the mechanisms of morbidity and mortality associated with anemia and transfusion in perioperative patient populations.
Drs. Hare and Mazer are Staff Anesthesiologists and Professors of Anesthesia, at St. Michael’s Hospital at the University of Toronto. Their clinical focus is to develop multimodal and inter-professional approaches to optimize patient outcomes through patient blood management strategies and clinical trials related to anemia, transfusion therapy, and cardiovascular outcomes. The long term research goals are to define mechanisms of anemia-induced cardiovascular morbidity and mortality, to optimize perioperative hemostasis and to design novel treatment strategies to prevent these adverse outcomes. Translational studies have identified integrative adaptive cellular (nNOS and HIF) and physiological mechanisms which promote organism survival during acute anemia. Their clinical research is currently focused on translational approaches to identify patient specific biomarkers of anemia-induced tissue hypoxia and to assess whether treatment of preoperative anemia can reduce morbidity and mortality associated with both anemia and red blood cell transfusions. Dr. Mazer has conducted large randomized clinical trials assessing important outcome in cardiovascular anesthesiology including the optimal use of antifibrinolytic agents to prevent acute blood loss (BART) and determination of the optimal hemoglobin threshold to transfuse patients undergoing cardiac surgery (TRICSIII). The overall goals are to reduce morbidity and mortality associated with acute and chronic anemia and RBC transfusion in perioperative patients with cardiovascular disease.
P: (416) 586-5270
Gregory M. T. Hare, MD, PhD: Principal Investigator